NCT05017571View on ClinicalTrials.gov

Colchicine to Suppress Inflammation and Improve Insulin Resistance in Adults and Adolescents With Obesity

PHASE2CompletedINTERVENTIONAL

Enrollment

152

Participants

Timeline

Start Date

November 8, 2021

Primary Completion Date

September 2, 2025

Study Completion Date

September 2, 2025

Conditions

ObesityInsulin ResistanceInflammation

Interventions

DRUG

Colchicine

Colchicine 1 capsule (0.6 mg) per day

DRUG

Placebo

Placebo 1 capsule per day

Trial Locations (1)

20892

National Institutes of Health Clinical Center, Bethesda

All Listed Sponsors

lead

Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)

NIH

NCT05017571 - Colchicine to Suppress Inflammation and Improve Insulin Resistance in Adults and Adolescents With Obesity | Biotech Hunter | Biotech Hunter